Amgen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.8%. The stock now trades at $350.73, marking a 18% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
1 источник
2 Reasons to Like AMGN and 1 to Stay Skeptical
👉
Finance KZ (Telegram)
Сегодня тенге немного растёт — 474,2 тенге за один доллар и 6,26 тенге за один российский рубль. #КурсТенге @FINANCEkaz
Рынок акций Казахстана: март 2026 на KASE – ликвидность вернулась, индекс остался на месте
Tengenomika (Telegram)
Если рынок акций представить как физическую систему, то капитализация – это его масса (сколько стоит весь рынок по текущим ценам) , а оборот – это скорость (насколько активно эта масса переходит из рук в руки) . В марте 2026 года на KASE рынок стал заметно тяжелее и ощутимо ускорился по оборотам, но
👉
Finance KZ (Telegram)
Закончили день небольшим укреплением — 471,14 тенге за один доллар и 6,17 тенге за один российский рубль . А вот объёмы под полмиллиарда долларов в день — это уже похоже новая реальность. В рубле сегодня вообще около рекордные показатели. #КурсТенге @FINANCEkaz
3 Reasons CGNX is Risky and 1 Stock to Buy Instead
Cognex has had an impressive run over the past six months as its shares have beaten the S&P 500 by 20.7%. The stock now trades at $53.89, marking a 23.2% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
3 Reasons AGL is Risky and 1 Stock to Buy Instead
agilon health trades at $26.45 per share and has stayed right on track with the overall market, gaining 9.6% over the last six months. At the same time, the S&P 500 has returned 5.1%.
3 Reasons A is Risky and 1 Stock to Buy Instead
Over the past six months, Agilent’s stock price fell to $118.28. Shareholders have lost 16.7% of their capital, which is disappointing considering the S&P 500 has climbed by 5.4%. This may have investors wondering how to approach the situation.
3 Reasons to Avoid ADM and 1 Stock to Buy Instead
Archer-Daniels-Midland has had an impressive run over the past six months as its shares have beaten the S&P 500 by 10.8%. The stock now trades at $70.16, marking a 13.4% gain. This performance may have investors wondering how to approach the situation.
